SilkRoad Technology Recognized as a Core Leader in 2020 Fosway 9-Grid™ for Talent Acquisition
28.5.2020 15:00:00 EEST | Business Wire | Press release
SilkRoad Technology, a global software and services platform that helps organisations attract, retain and align people to its business, today announced its recognition as a Core Leader in the 2020 Fosway 9-Grid™ for Talent Acquisition. This position acknowledges SilkRoad Technology for growth and innovation in its talent experience capabilities, as well as for the company's continued customer growth, success and advocacy across the European market.
SilkRoad Technology’s Talent Acquisition services and software help organisations optimise talent by attracting the right calibre of candidate to the business. HR and business decision-makers can streamline recruiting processes from requisition to job offer through SilkRoad’s scalable, personalised and on-brand solution that drives engagement and retention. Once the right talent is identified and secured, SilkRoad’s onboarding solution provides clarity, alignment and enablement to employees which helps accelerate revenue for efficient cost management in the midst of evolving workforce transformation.
“Being viewed as a Core Leader by Fosway is a great achievement for SilkRoad Technology. The Talent acquisition marketplace continues to face significant change and disruption particularly in these extremely difficult times. That’s why we continue to heavily invest finances and staff time in the development of our solution’s, so they are fit not only for today’s business challenges but also agile enough to evolve for the challenges of tomorrow as well,” said Colin Larter, Senior Director, SilkRoad EMEA.
The Fosway Group 9-Grid™ is a five-dimensional market analysis model that helps organisations understand the relative position of solutions and providers in the learning and talent systems market. It is based on Fosway Group’s independent research in the HR, talent and learning market throughout the past 20 years, and draws on insight and experience of its Corporate Research Network. The Corporate Research Network is a group of HR and learning professionals, who among them represent more than 150 of Europe’s leading companies. The 2018 Fosway 9-Grid™ for Talent Acquisition is available here.
“Silkroad is a new addition to the 2020 Fosway 9-Grid™ for Talent Acquisition. Whilst Silkroad plays in multiple parts of the talent lifecycle, its specialist focus on onboarding is central to our assessment and rating as a Core Leader,” said David Wilson, CEO of Fosway Group. “SilkRoad’s recognition reflects its proven capability to provide European companies with much needed expertise in a critical area of success.”
About Fosway
Fosway Group is Europe's #1 HR Industry Analyst. The Fosway 9-Grid provides a unique assessment of the principal learning and talent supply options available to organisations in EMEA. The 9-Grids help European buyers demystify supplier decisions for next gen HR, Talent and Learning. Fosway Group have provided expert independent advice to corporate clients for over 20 years.
Visit the Fosway website at www.fosway.com for more information on Fosway Group's research and services.
About SilkRoad Technology
Since 2003, SilkRoad Technology’s software and services platform helps our clients attract, retain and align people to their business. Our solutions start with Global Client Services to provide strategic HR and business expertise. SilkRoad then designs secure solutions tailored to your business requirements at scale for global companies. We deliver personalised experiences for employees to drive engagement across the employment lifecycle to enable measurable and better business outcomes.
For more information, visit www.silkroadtechnology.com, follow on Twitter @SilkRoadTweets or call 866-329-336. (U.S. toll free) or +1-312-574-3700.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200528005286/en/
Contact information
Karl Fruecht
847.732.3920
Karl.Fruecht@silkroad.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 12:47:00 EEST | Press release
Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food products. Within this inspiring premise, Good Food Makers confirms itself as one of the main levers f
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 11:16:00 EEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 09:00:00 EEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
